ALT - Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions | Benzinga
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association's (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024.
Details for the oral presentations are as follows:
| Session Title: |
| Leveling Up Incretin-Based Therapy in Type 2 Diabetes |
| Session Date/Time: |
| Saturday, June 22, 2024, 4:30 PM - 6:00 PM |
| Presentation Title: |
| Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids |
| Presenter: |